A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2019 Dec 22

PMID 31861827

Citations 27

Authors

Carmen Martinez

Yasmina Juarranz

Irene Gutierrez-Canas

Mar Carrion

Selene Perez-Garcia

Raul Villanueva-Romero

David Castro

Amalia Lamana

Mario Mellado

Isidoro Gonzalez-Alvaro

Rosa P Gomariz

Affiliations

Soon will be listed here.

Abstract

The neuroendocrine and immune systems are coordinated to maintain the homeostasis of the organism, generating bidirectional communication through shared mediators and receptors. Vasoactive intestinal peptide (VIP) is the paradigm of an endogenous neuropeptide produced by neurons and endocrine and immune cells, involved in the control of both innate and adaptive immune responses. Exogenous administration of VIP exerts therapeutic effects in models of autoimmune/inflammatory diseases mediated by G-protein-coupled receptors (VPAC1 and VPAC2). Currently, there are no curative therapies for inflammatory and autoimmune diseases, and patients present complex diagnostic, therapeutic, and prognostic problems in daily clinical practice due to their heterogeneous nature. This review focuses on the biology of VIP and VIP receptor signaling, as well as its protective effects as an immunomodulatory factor. Recent progress in improving the stability, selectivity, and effectiveness of VIP/receptors analogues and new routes of administration are highlighted, as well as important advances in their use as biomarkers, contributing to their potential application in precision medicine. On the 50th anniversary of VIP's discovery, this review presents a spectrum of potential clinical benefits applied to inflammatory and autoimmune diseases.

Citing Articles

Ligands for Intestinal Intraepithelial T Lymphocytes in Health and Disease.

Hada A, Xiao Z Pathogens. 2025; 14(2).

PMID: 40005486 PMC: 11858322. DOI: 10.3390/pathogens14020109.

Associations between sleep traits and colorectal cancer: a mendelian randomization analysis.

Meng X, Fan E, Lv D, Yang Y, Liu S Front Oncol. 2025; 15:1416243.

PMID: 39980544 PMC: 11839420. DOI: 10.3389/fonc.2025.1416243.

The role of neuropeptides in cutaneous wound healing: a focus on mechanisms and neuropeptide-derived treatments.

Xing L, Chen B, Qin Y, Li X, Zhou S, Yuan K Front Bioeng Biotechnol. 2024; 12:1494865.

PMID: 39539691 PMC: 11557334. DOI: 10.3389/fbioe.2024.1494865.

Genetic variants regulating the immune response improve the prediction of COVID-19 severity provided by clinical variables.

Delgado-Wicke P, Fernandez de Cordoba-Onate S, Roy-Vallejo E, Alegria-Carrasco E, Rodriguez-Serrano D, Lamana A Sci Rep. 2024; 14(1):20728.

PMID: 39237611 PMC: 11377536. DOI: 10.1038/s41598-024-71476-2.

Emerging pharmacological targets for alcohol use disorder.

Brockway D, Crowley N Alcohol. 2024; 121:103-114.

PMID: 39069210 PMC: 11638729. DOI: 10.1016/j.alcohol.2024.07.007.

References

McCulloch D, Lutz E, Johnson M, Mackenzie C, Mitchell R . Differential activation of phospholipase D by VPAC and PAC1 receptors. Ann N Y Acad Sci. 2001; 921:175-85. DOI: 10.1111/j.1749-6632.2000.tb06964.x. View

Abad C, Tan Y, Cheung-Lau G, Nobuta H, Waschek J . VIP deficient mice exhibit resistance to lipopolysaccharide induced endotoxemia with an intrinsic defect in proinflammatory cellular responses. PLoS One. 2012; 7(5):e36922. PMC: 3355097. DOI: 10.1371/journal.pone.0036922. View

Bartok B, Firestein G . Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev. 2010; 233(1):233-55. PMC: 2913689. DOI: 10.1111/j.0105-2896.2009.00859.x. View

Felson D, Smolen J, Wells G, Zhang B, van Tuyl L, Funovits J . American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011; 63(3):573-86. PMC: 3115717. DOI: 10.1002/art.30129. View

Fernandez-Martin A, Gonzalez-Rey E, Chorny A, Ganea D, Delgado M . Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis. Eur J Immunol. 2006; 36(2):318-26. DOI: 10.1002/eji.200535430. View

Roca V, Calafat M, Larocca L, Ramhorst R, Farina M, Franchi A . Potential immunomodulatory role of VIP in the implantation sites of prediabetic nonobese diabetic mice. Reproduction. 2009; 138(4):733-42. DOI: 10.1530/REP-09-0171. View

Lu J, Zheng M, Yan J, Chen Y, Pan J . Effects of vasoactive intestinal peptide on phenotypic and functional maturation of dendritic cells. Int Immunopharmacol. 2008; 8(10):1449-54. DOI: 10.1016/j.intimp.2008.06.002. View

Arranz A, Abad C, Juarranz Y, Torroba M, Rosignoli F, Leceta J . Effect of VIP on TLR2 and TLR4 expression in lymph node immune cells during TNBS-induced colitis. Ann N Y Acad Sci. 2006; 1070:129-34. DOI: 10.1196/annals.1317.001. View

Vessillier S, Adams G, Montero-Melendez T, Jones R, Seed M, Perretti M . Molecular engineering of short half-life small peptides (VIP, αMSH and γ₃MSH) fused to latency-associated peptide results in improved anti-inflammatory therapeutics. Ann Rheum Dis. 2011; 71(1):143-9. DOI: 10.1136/annrheumdis-2011-200100. View

10.

Dickson L, Aramori I, McCulloch J, Sharkey J, Finlayson K . A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology. Neuropharmacology. 2006; 51(6):1086-98. DOI: 10.1016/j.neuropharm.2006.07.017. View

11.

ODonnell M, Garippa R, Rinaldi N, Selig W, SIMKO B, Renzetti L . Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part I: In vitro and in vivo bronchodilator studies. J Pharmacol Exp Ther. 1994; 270(3):1282-8. View

12.

Abad C, Tan Y, Lopez R, Nobuta H, Dong H, Phan P . Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2010; 107(45):19555-60. PMC: 2984164. DOI: 10.1073/pnas.1007622107. View

13.

Gomariz R, Arranz A, Juarranz Y, Gutierrez-Canas I, Garcia-Gomez M, Leceta J . Regulation of TLR expression, a new perspective for the role of VIP in immunity. Peptides. 2007; 28(9):1825-32. DOI: 10.1016/j.peptides.2007.07.005. View

14.

Straub R, Bijlsma J, Masi A, Cutolo M . Role of neuroendocrine and neuroimmune mechanisms in chronic inflammatory rheumatic diseases--the 10-year update. Semin Arthritis Rheum. 2013; 43(3):392-404. DOI: 10.1016/j.semarthrit.2013.04.008. View

15.

Gutierrez-Canas I, Juarranz M, Collado B, Rodriguez-Henche N, Chiloeches A, Prieto J . Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K. Prostate. 2004; 63(1):44-55. DOI: 10.1002/pros.20173. View

16.

Centola M, Cavet G, Shen Y, Ramanujan S, Knowlton N, Swan K . Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS One. 2013; 8(4):e60635. PMC: 3621826. DOI: 10.1371/journal.pone.0060635. View

17.

Dickson L, Finlayson K . VPAC and PAC receptors: From ligands to function. Pharmacol Ther. 2008; 121(3):294-316. DOI: 10.1016/j.pharmthera.2008.11.006. View

18.

Jimeno R, Gomariz R, Garin M, Gutierrez-Canas I, Gonzalez-Alvaro I, Carrion M . The pathogenic Th profile of human activated memory Th cells in early rheumatoid arthritis can be modulated by VIP. J Mol Med (Berl). 2014; 93(4):457-67. PMC: 4366555. DOI: 10.1007/s00109-014-1232-4. View

19.

Chu T, Orlowski M . Soluble metalloendopeptidase from rat brain: action on enkephalin-containing peptides and other bioactive peptides. Endocrinology. 1985; 116(4):1418-25. DOI: 10.1210/endo-116-4-1418. View

20.

ODorisio M, ODorisio T, Cataland S, Balcerzak S . Vasoactive intestinal polypeptide as a biochemical marker for polymorphonuclear leukocytes. J Lab Clin Med. 1980; 96(4):666-72. View